S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$35.10
-1.17 (-3.23%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$34.96
$36.55
50-Day Range
$28.58
$41.39
52-Week Range
$27.00
$81.13
Volume
480,063 shs
Average Volume
599,520 shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.00

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.72 Rating Score
Upside/​Downside
102.3% Upside
$71.00 Price Target
Short Interest
Healthy
10.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Arvinas in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.81) to ($5.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

305th out of 1,029 stocks

Pharmaceutical Preparations Industry

143rd out of 501 stocks

ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 (ARVN)
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Arvinas (NASDAQ:ARVN) Rating Reiterated by Cantor Fitzgerald
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Brokerages Set Arvinas, Inc. (NASDAQ:ARVN) Price Target at $71.00
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 10.4%
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Arvinas to Present at Upcoming Conferences
Why Arvinas (ARVN) Might Surprise This Earnings Season
Arvinas Gives Back to Local Greater New Haven Community
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
11/08/2022
Today
2/04/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.00
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+102.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
18 Analysts

Profitability

Net Income
$-191,000,000.00
Net Margins
-225.34%
Pretax Margin
-216.24%

Debt

Sales & Book Value

Annual Sales
$46.70 million
Book Value
$14.78 per share

Miscellaneous

Free Float
51,748,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
1.77

Key Executives

  • John G. HoustonJohn G. Houston
    President, Chief Executive Officer & Director
  • Lisa Sinclair
    Senior Vice President-Corporate Operations
  • Sean A. CassidySean A. Cassidy
    Chief Financial Officer
  • Ian TaylorIan Taylor
    Chief Scientific Officer
  • Ronald PeckRonald Peck
    Chief Medical Officer













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

18 analysts have issued 12-month price targets for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's share price to reach $71.00 in the next twelve months. This suggests a possible upside of 102.3% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have increased by 2.6% and is now trading at $35.10.
View the best growth stocks for 2023 here
.

Are investors shorting Arvinas?

Arvinas saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 4,660,000 shares, a decrease of 10.4% from the December 31st total of 5,200,000 shares. Based on an average daily volume of 553,300 shares, the short-interest ratio is presently 8.4 days. Approximately 10.2% of the company's shares are short sold.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 8th. The company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.26. The business had revenue of $30.30 million for the quarter, compared to analysts' expectations of $44.20 million. Arvinas had a negative trailing twelve-month return on equity of 36.12% and a negative net margin of 225.34%.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.68%), Emerald Mutual Fund Advisers Trust (0.46%), Bank of Montreal Can (0.00%), State of New Jersey Common Pension Fund D (0.11%), Allspring Global Investments Holdings LLC (0.06%) and Joel Isaacson & Co. LLC (0.06%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $35.10.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.87 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.76) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 2/4/2023 by MarketBeat.com Staff